Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Sep 1;16(9):e68421.
doi: 10.7759/cureus.68421. eCollection 2024 Sep.

BPaLM Regimen Against Drug-Resistant Tuberculosis in India: A Need of the Hour

Sankalp Yadav  1
Affiliations
Editorial

BPaLM Regimen Against Drug-Resistant Tuberculosis in India: A Need of the Hour

Sankalp Yadav. Cureus. .

Abstract

India has a high burden of drug-resistant tuberculosis (DR-TB) cases. The management of this severe form of TB is associated with a number of issues like long treatment durations, high pill burden, and multiple adverse drug reactions. Efforts are on through various research studies and trials for finding solutions to the issues linked to the current drug regimens against drug-resistant tuberculosis. One such remarkable development is the introduction of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM)-based regimens to fight against two of the most severe forms of tuberculosis, i.e., multidrug- and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB). This editorial throws light on this newer regimen and discusses the same in the Indian context.

Keywords: bedaquiline; bpalm; extensively drug-resistant tuberculosis (xdr-tb); linezolid; moxifloxacin; multidrug-resistant tuberculosis (mdr-tb); pretomanid; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

    1. Starting an all-oral longer regimen in a primary multidrug-resistant pulmonary tuberculosis patient at a district tuberculosis center for the first time: a rare case. Yadav S. Cureus. 2022;14:0. - PMC - PubMed
    1. Correction: global adoption of 6-month drug-resistant TB regimens: projected uptake by 2026. PLoS One. 2024;19:0. - PMC - PubMed
    1. Govt to roll out training programme for novel tb drug regimen: what it means for drug-resistant patients? [ Aug; 2024 ]. August 20, 2024. https://indianexpress.com/article/health-wellness/rollout-of-new-regimen... https://indianexpress.com/article/health-wellness/rollout-of-new-regimen...
    1. Savings from the introduction of BPaL and BPaLM regimens at the country level. Auer C, Gupta A, Malbacius C, et al. IJTLD Open. 2024;1:314–319. - PMC - PubMed
    1. Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol. Padmapriyadarsini C, Devaleenal B, Ponnuraja C, et al. BMJ Open. 2022;12:0. - PMC - PubMed

Publication types

LinkOut - more resources